Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05872256 · ClinicalTrials.gov registry record · Phase 4
A Demonstration of the Hair and Scalp Benefits of Duobrii in Scalp Psoriasis
A Phase 4 study of Scalp Psoriasis, sponsored by Dermatology Consulting Services, P.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05872256: Completed Phase 4 study of Scalp Psoriasis, sponsored by Dermatology Consulting Services, P.
NCT05872256 is a Phase 4 study of Scalp Psoriasis that has completed, run by Dermatology Consulting Services, P. The registered enrollment target is 20 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05872256, a Phase 4 study of Scalp Psoriasis, has completed, sponsored by Dermatology Consulting Services, P.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The objectives of this research are to demonstrate the following:1. To demonstrate improvement in hair growth and hair appearance following 12 weeks of once daily treatment with tazarotene/halobetasol lotion in patients with moderate to severe scalp psoriasis.2. To demonstrate improvement in scalp itch reduction following 12 weeks of once daily treatment with tazarotene/halobetasol lotion in patients with moderate to severe scalp psoriasis.3. To pictorially demonstrate improvement in moderate to severe scalp psoriasis with 12 weeks of once daily treatment with tazarotene/halobetasol lotion.4. To assessment patient perceptions of the value of a lotion in the treatment of moderate to severe scalp psoriasis.
Primary Outcome
Improvement in hair growth due to scalp psoriasis treatment
Conditions Studied
Interventions
- DRUG 0.045% Tazarotene/0.01% Halobetasol Lotion
Study Locations (1)
North Carolina
- Dermatology Consulting Services, PLLC - High Point
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-06-01 |
| Est. Completion | 2023-11-13 |
| Phase | Phase 4 |
What the finished NCT05872256 record still lists
NCT05872256 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Scalp Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which 0.045% Tazarotene/0.01% Halobetasol Lotion is the first listed.
NCT05872256 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05872256 about?
NCT05872256 is a clinical study titled "A Demonstration of the Hair and Scalp Benefits of Duobrii in Scalp Psoriasis". The objectives of this research are to demonstrate the following:1. To demonstrate improvement in hair growth and hair appearance following 12 weeks of once daily treatment with tazarotene/halobetasol lotion in patients with moderate to severe scalp psoriasis.2. To demonstrate improvement in scalp i...
What is the current status of trial NCT05872256?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2023-06-01. Estimated completion is 2023-11-13.
What conditions does trial NCT05872256 study?
This clinical trial studies the following conditions: Scalp Psoriasis.
What interventions are being tested in trial NCT05872256?
The interventions under investigation include: 0.045% Tazarotene/0.01% Halobetasol Lotion (DRUG).
Who is sponsoring clinical trial NCT05872256?
This trial is sponsored by Dermatology Consulting Services, P, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05872256 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Scalp Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05872256's enrollment target sits among peer trials
20 1753rd of 2000 higher than 167 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI